De M. Martins

Manguinhos, RJ, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Immunogenicity, safety and immunological memory of a Brazilian meningococcal C conjugate vaccine on a phase II clinical trial.

Immunogenicity, safety and immunological memory of a Brazilian meningococcal C conjugate vaccine on a phase II clinical trial.

Journal: Vaccine

Published: January 23, 2025

Dr. Reinaldo de Menezes Martins: six decades dedicated to vaccination.

Dr. Reinaldo de Menezes Martins: six decades dedicated to vaccination.

Journal: Cadernos de saude publica

Published: July 10, 2020

Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Journal: Frontiers in immunology

Published: September 09, 2019

Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.

Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.

Journal: Frontiers in immunology

Published: June 26, 2019

Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Journal: Frontiers in immunology

Published: March 19, 2019

Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines.

Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines.

Journal: The Journal of experimental medicine

Published: December 12, 2018

Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination.

Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination.

Journal: PLoS neglected tropical diseases

Published: October 05, 2017

Booster dose after 10 years is recommended following 17DD-YF primary vaccination.

Booster dose after 10 years is recommended following 17DD-YF primary vaccination.

Journal: Human vaccines & immunotherapeutics

Published: September 12, 2015

Historical review of clinical vaccine studies at Oswaldo Cruz Institute and Oswaldo Cruz Foundation--technological development issues.

Historical review of clinical vaccine studies at Oswaldo Cruz Institute and Oswaldo Cruz Foundation--technological development issues.

Journal: Memorias do Instituto Oswaldo Cruz

Published: September 22, 2014

Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil.

Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil.

Journal: Vaccine

Published: January 20, 2014

Immune response to the mumps component of the MMR vaccine in the routine of immunisation services in the Brazilian National Immunisation Program.

Immune response to the mumps component of the MMR vaccine in the routine of immunisation services in the Brazilian National Immunisation Program.

Journal: Memorias do Instituto Oswaldo Cruz

Published: July 04, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026